Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 BioCryst to Report Third Quarter 2026 Financial Results on November 4 Oct 21, 2026 Read More BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE Oct 21, 2026 Read More BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth Oct 05, 2026 Read More BioCryst to Present at Upcoming Investor Conference Sep 01, 2026 Read More BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan Aug 25, 2026 Read More BioCryst Reports Second Quarter 2026 Financial Results Aug 05, 2026 Read More BioCryst to Report Second Quarter 2026 Financial Results on August 5 Jul 22, 2026 Read More BioCryst Appoints David W. Jenkins as Chief Scientific Officer Jul 15, 2026 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jul 02, 2026 Read More BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility Jun 29, 2026 Read More
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE Oct 21, 2026 Read More
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth Oct 05, 2026 Read More
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility Jun 29, 2026 Read More